×
About 14,148 results

ALLMedicine™ Alzheimer Disease Center

Research & Reviews  4,960 results

The cognitive performance in the Phototest is predictor of biological markers of Alzhei...
https://doi.org/10.1002/gps.5792
International Journal of Geriatric Psychiatry; Ismael CM, José M BL et. al.

Aug 10th, 2022 - The abnormal cerebrospinal fluid levels of biomarkers, such as β-amyloid and phosphorylated tau (pTau), support the biological diagnosis of Alzheimer Disease (AD) independently of its clinical stage. However, this invasive exam cannot be extensive...

To My Husband With Alzheimer Disease.
https://doi.org/10.1001/jama.2022.9184
JAMA DePew R

Aug 10th, 2022 - To My Husband With Alzheimer Disease.|2022|DePew R,|

Serial neurocognitive changes following transcatheter aortic valve replacement: compari...
https://doi.org/10.18632/aging.204202
Aging Ko TY, Kao HL et. al.

Aug 9th, 2022 - Data comparing the neurocognitive trajectory between low and intermediate-high risk patients following transcatheter aortic valve replacement (TAVR) is never reported. To report serial neurocognitive changes up to 1 year post-TAVR in low and inter...

The challenges of anti-tau therapeutics in Alzheimer disease.
https://doi.org/10.1038/s41582-022-00702-0
Nature Reviews. Neurology; Panza F, Lozupone M

Aug 9th, 2022 - The challenges of anti-tau therapeutics in Alzheimer disease.|2022|Panza F,Lozupone M,|

The Gut Microbiome and Alzheimer's Disease: Complex and Bidirectional Interactions.
https://doi.org/10.1016/j.neubiorev.2022.104814
Neuroscience and Biobehavioral Reviews; Tarawneh R, Penhos E

Aug 8th, 2022 - Structural and functional alterations to the gut microbiome, referred to as gut dysbiosis, have emerged as potential key mediators of neurodegeneration and Alzheimer disease (AD) pathogenesis through the "gut -brain" axis. Emerging data from anima...

see more →

Guidelines  5 results

ACR Appropriateness Criteria® Dementia.
https://doi.org/10.1016/j.jacr.2020.01.040
Journal of the American College of Radiology : JACR; , Moonis G et. al.

May 7th, 2020 - Degenerative disease of the central nervous system is a growing public health concern. The primary role of neuroimaging in the workup of patients with probable or possible Alzheimer disease has typically been to exclude other significant intracran...

Falls Risk and Alzheimer Disease: A Patient Guide.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252520
Archives of Physical Medicine and Rehabilitation; Kahya M, Sood P et. al.

Mar 3rd, 2020 - Falls Risk and Alzheimer Disease: A Patient Guide.|2020|Kahya M,Sood P,Devos H,Krishnan S,Hirsch MA,|

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cogn...
https://doi.org/10.1016/j.jalz.2013.06.001
Alzheimer's & Dementia : the Journal of the Alzheimer's A... Johnson KA, Minoshima S et. al.

Jul 3rd, 2013 - Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and S...

Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326653
Genetics in Medicine : Official Journal of the American C... Goldman JS, Hahn SE et. al.

May 18th, 2011 - Alzheimer disease is the most common cause of dementia. It occurs worldwide and affects all ethnic groups. The incidence of Alzheimer disease is increasing due, in part, to increased life expectancy and the aging baby boomer generation. The averag...

Responding to requests from adult patients for neuroenhancements: guidance of the Ethic...
https://doi.org/10.1212/WNL.0b013e3181beecfe
Neurology Larriviere D, Williams MA et. al.

Sep 25th, 2009 - In the last decade, persons who have no diagnosed medical or mental health condition are increasingly seeking and utilizing, for the ostensible purpose of enhancing their memory or cognitive skills, prescription drugs that were originally develope...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  236 results

Hyperbaric Oxygen Therapy for Prodromal Alzheimer´s Disease With Cerebrovascular Disease
https://clinicaltrials.gov/ct2/show/NCT05349318

Jul 26th, 2022 - Alzheimer disease is characterised by cognitive, mental and functional disability that is expected to progress until the patient is fully dependent on others for activities of daily living. The pathology begins many years until the cognitive sympt...

Comparison of OCTA Factors in Patients With or Without Amyloid Pathology: A Prospective Study
https://clinicaltrials.gov/ct2/show/NCT05475158

Jul 26th, 2022 - Alzheimer disease dementia (ADD) is the most common neurodegenerative disease dementia in elderly population associated with the accumulation of beta-amyloid (Aβ) plaques and tau neurofibrillary tangles (NFTs). Diagnostic biomarkers reflecting und...

Falls: A Marker of Preclinical AD
https://clinicaltrials.gov/ct2/show/NCT04949529

Jul 25th, 2022 - Alzheimer disease (AD) is a slowly progressive neurodegenerative disease. Conversion to symptomatic AD occurs slowly over years through a series of preclinical stages marked by changes in molecular biomarkers. It is unknown whether functional mobi...

Multidomain Intervention Programs for Older People With Dementia With Dementia
https://clinicaltrials.gov/ct2/show/NCT04948450

Jul 21st, 2022 - After initial screening, participants and their caregivers will receive a complete explanation of the purpose, risks, and procedures of the study and sign a written informed consent if they show interest in participating. Those agreeing will be ra...

Helicobacter Pylori Eradication Therapy for Epileptic Children
https://clinicaltrials.gov/ct2/show/NCT05297695

Jul 21st, 2022 - Helicobacter pylori (H. pylori) is a spiral-shaped Gram-negative bacterium, which causes chronic infection in more than 50% of human population. H. pylori infection is associated with several gastrointestinal disorders, such as gastritis and gastr...

see more →

News  453 results

A Special Supplement on Hot Topics in Primary Care 2022
https://www.mdedge.com/familymedicine/article/254496/special-supplement-hot-topics-primary-care-2022
MDedge Family Medicine;

Jul 25th, 2022 - Hot Topics in Primary Care 2022 is a resource that explores the newest developments in primary care topics that impact your daily clinical practice. Click on the link below to access the entire supplement.

Aluminum: The 2022 American Contact Dermatitis Society Allergen of the Year
https://www.mdedge.com/dermatology/article/256133/contact-dermatitis/aluminum-2022-american-contact-dermatitis-society
Danielle E. Novack, BA, Jiade Yu, MD et. al.

Jul 8th, 2022 - No time of the year is more exciting than the unveiling of the American Contact Dermatitis Society Allergen of the Year. Sometimes the selected allergen represents a completely novel cause of allergic contact dermatitis (ACD) with an unpronounceab.

An Imminent Risk Factor for Alzheimer's Disease?
https://www.medscape.com/viewarticle/974596

May 25th, 2022 - The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaways The clinical value of biologic criteria ― global amyloid burden (A), composite of temporal region of tau PET uptake (T),...

Risk of developing dementia is similar with tofacitinib, tocilizumab, or TNFi vs. abatacept in RA
https://www.mdedge.com/rheumatology/article/254915/rheumatoid-arthritis/risk-developing-dementia-similar-tofacitinib

May 24th, 2022 - Key clinical point: Treatment with tofacitinib, tocilizumab, or tumor necrosis factor inhibitors (TNFi) vs. abatacept did not reduce the risk of developing Alzheimer disease and related dementia (ADRD) in patients with rheumatoid arthritis (RA).

Patients asking about APOE gene test results? Here’s what to tell them
https://www.mdedge.com/familymedicine/article/254542/preventive-care/patients-asking-about-apoe-gene-test-results-heres
MDedge Family Medicine; Shana D. Stites, PsyD, MS, MA, Nicholas M. Vogt, MD, PhD et. al.

May 11th, 2022 - Advances in Alzheimer disease (AD) genes and biomarkers now allow older adults to undergo testing and learn about their risk for AD. 1 Current routes for doing so include testing in cardiology, screening for enrollment in secondary prevention trial.

see more →